AAAAAA

   
Results: 1-25 | 26-50 | 51-68 |
Results: 51-68/68
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma
Authors: O'Day, SJ Gammon, G Boasberg, PD Martin, MA Kristedja, TS Guo, M Stern, S Edwards, S Fournier, P Weisberg, M Cannon, M Fawzy, NW Johnson, TD Essner, R Foshag, LJ Morton, DL
Citation: Sj. O'Day et al., Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma, J CL ONCOL, 17(9), 1999, pp. 2752-2761
Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients
Authors: Bostick, PJ Morton, DL Turner, RR Huynh, KT Wang, HJ Elashoff, R Essner, R Hoon, DSB
Citation: Pj. Bostick et al., Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients, J CL ONCOL, 17(10), 1999, pp. 3238-3244
Gamma knife radiosurgery for metastatic melanoma: An analysis of survival,outcome, and complications
Authors: Lavine, SD Petrovich, Z Cohen-Gadol, AA Masri, LS Morton, DL O'Day, SJ Essner, R Zelman, V Yu, C Luxton, G Apuzzo, MLJ
Citation: Sd. Lavine et al., Gamma knife radiosurgery for metastatic melanoma: An analysis of survival,outcome, and complications, NEUROSURGER, 44(1), 1999, pp. 59-64
Critical review of the sentinel node hypothesis
Authors: Morton, DL Ollila, DW
Citation: Dl. Morton et Dw. Ollila, Critical review of the sentinel node hypothesis, SURGERY, 126(5), 1999, pp. 815-819
Carbon dye as an adjunct to isosulfan blue dye for sentinel lymph node dissection
Authors: Lucci, A Turner, RR Morton, DL
Citation: A. Lucci et al., Carbon dye as an adjunct to isosulfan blue dye for sentinel lymph node dissection, SURGERY, 126(1), 1999, pp. 48-53
Metastasectomy for recurrent stage IV melanoma
Authors: Ollila, DW Hsueh, EC Stern, SL Morton, DL
Citation: Dw. Ollila et al., Metastasectomy for recurrent stage IV melanoma, J SURG ONC, 71(4), 1999, pp. 209-213
Tumor doubling time and survival
Authors: Ollila, DW Morton, DL
Citation: Dw. Ollila et Dl. Morton, Tumor doubling time and survival, J SURG ONC, 71(4), 1999, pp. 249-249
IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlatewith survival of melanoma patients
Authors: Takahashi, T Johnson, TD Nishinaka, Y Morton, DL Irie, RF
Citation: T. Takahashi et al., IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlatewith survival of melanoma patients, J INVES DER, 112(2), 1999, pp. 205-209
Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients
Authors: Fujiwara, Y Chi, DDJ Wang, HJ Keleman, P Morton, DL Turner, R Hoon, DSB
Citation: Y. Fujiwara et al., Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients, CANCER RES, 59(7), 1999, pp. 1567-1571
Survival of patients with melanoma of the lower extremity decreases with distance from the trunk
Authors: Hsueh, EC Lucci, A Qi, K Morton, DL
Citation: Ec. Hsueh et al., Survival of patients with melanoma of the lower extremity decreases with distance from the trunk, CANCER, 85(2), 1999, pp. 383-388
Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases
Authors: Hsueh, EC Nathanson, L Foshag, LJ Essner, R Nizze, JA Stern, SL Morton, DL
Citation: Ec. Hsueh et al., Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases, CANCER, 85(10), 1999, pp. 2160-2169
Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma
Authors: Morton, DL Ollila, DW Hsueh, EC Essner, R Gupta, RK
Citation: Dl. Morton et al., Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma, CA-A CANC J, 49(2), 1999, pp. 101
Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma - A multicenter trial
Authors: Morton, DL Thompson, JF Essner, R Elashoff, R Stern, SL Nieweg, OE Roses, DF Karakousis, CP Mozzillo, N Reintgen, D Wang, HJ Glass, EC Cochran, AJ
Citation: Dl. Morton et al., Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma - A multicenter trial, ANN SURG, 230(4), 1999, pp. 453-463
Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial - Discussion
Authors: Balch, CM Morton, DL Bland, KI Wanebo, HJ
Citation: Cm. Balch et al., Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial - Discussion, ANN SURG, 230(4), 1999, pp. 463-465
Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms
Authors: Bilchik, AJ Giuliano, A Essner, R Bostick, P Kelemen, P Foshag, LJ Sostrin, S Turner, RR Morton, DL
Citation: Aj. Bilchik et al., Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms, CA J SCI AM, 4(6), 1998, pp. 351-358
Active immunotherapy with allogeneic tumor cell vaccines: Present status
Authors: Chan, AD Morton, DL
Citation: Ad. Chan et Dl. Morton, Active immunotherapy with allogeneic tumor cell vaccines: Present status, SEMIN ONCOL, 25(6), 1998, pp. 611-622
Tumor doubling time: A selection factor for pulmonary resection of metastatic melanoma
Authors: Ollila, DW Stern, SL Morton, DL
Citation: Dw. Ollila et al., Tumor doubling time: A selection factor for pulmonary resection of metastatic melanoma, J SURG ONC, 69(4), 1998, pp. 206-211
Anti-tyrosinase-related protein-2 immune response in vitiligo patients andmelanoma patients receiving active-specific immunotherapy
Authors: Okamoto, T Irie, RF Fujii, S Huang, SKS Nizze, AJ Morton, DL Hoon, DSB
Citation: T. Okamoto et al., Anti-tyrosinase-related protein-2 immune response in vitiligo patients andmelanoma patients receiving active-specific immunotherapy, J INVES DER, 111(6), 1998, pp. 1034-1039
Risultati: 1-25 | 26-50 | 51-68 |